{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:57:57Z","timestamp":1768586277697,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2019.101133","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T12:54:07Z","timestamp":1575636847000},"page":"101133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Atypical CML- the role of morphology and precision genomics"],"prefix":"10.1016","volume":"33","author":[{"given":"Terra","family":"Lasho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2019.101133_bib1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101133_bib2","first-page":"250","volume":"vol. 2011","author":"Vardiman","year":"2011"},{"issue":"20","key":"10.1016\/j.beha.2019.101133_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2019.101133_bib4","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2019.101133_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","article-title":"Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database","volume":"6","author":"Giri","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"10.1016\/j.beha.2019.101133_bib6","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101133_bib7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hon.2501","article-title":"Atypical chronic myeloid leukaemia: a case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group","author":"Drozd-Sokolowska","year":"2018","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V75.2.445.445","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course","volume":"75","author":"Kurzrock","year":"1990","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2019.101133_bib9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.beha.2019.101133_bib10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101133_bib11","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0950-3536(87)80031-8","article-title":"Haematological classification of the chronic myeloid leukaemias","volume":"1","author":"Shepherd","year":"1987","journal-title":"Bailliere Clin Haematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hernandez","year":"2000","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.101133_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2141.1996.396933.x","article-title":"Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?","volume":"92","author":"Oscier","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.1995.tb05157.x","article-title":"Philadelphia chromosome-negative chronic myeloid leukaemia: a report of 14 new cases","volume":"90","author":"Costello","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000203629","article-title":"A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature","volume":"98","author":"Misialek","year":"1997","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.beha.2019.101133_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int J Hematol"},{"issue":"23","key":"10.1016\/j.beha.2019.101133_bib19","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2019.101133_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101133_bib21","doi-asserted-by":"crossref","first-page":"12475","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.beha.2019.101133_bib23","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"7488","key":"10.1016\/j.beha.2019.101133_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.beha.2019.101133_bib25","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"149","key":"10.1016\/j.beha.2019.101133_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.beha.2019.101133_bib27","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.beha.2019.101133_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2016-03-707745","article-title":"Architectural and functional heterogeneity of hematopoietic stem\/progenitor cells in non-del(5q) myelodysplastic syndromes","volume":"129","author":"Chesnais","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101133_bib32","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.beha.2019.101133_bib33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2019.101133_bib34","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.101133_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3324\/haematol.2013.091249","article-title":"Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1\/2 mutations","volume":"99","author":"Lin","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2019.101133_bib36","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.beha.2019.101133_bib37","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMc1503143","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Delhommeau","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2019.101133_bib38","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2019.101133_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2019.101133_bib40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2019.101133_bib41","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101133_bib42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOH.0000000000000021","article-title":"Making sense of the myelodysplastic\/myeloproliferative neoplasms overlap syndromes","volume":"21","author":"Tiu","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.beha.2019.101133_bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What's different about atypical CML and chronic neutrophilic leukemia?","author":"Dao","year":"2015","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.beha.2019.101133_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"issue":"24","key":"10.1016\/j.beha.2019.101133_bib46","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2019.101133_bib47","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2019.101133_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101133_bib49","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2019.101133_bib50","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.101133_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40364-017-0113-8","article-title":"SETBP1 mutations as a biomarker for myelodysplasia\/myeloproliferative neoplasm overlap syndrome","volume":"5","author":"Linder","year":"2017","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.beha.2019.101133_bib53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2019.101133_bib52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101133_bib54","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Canc J"},{"issue":"1","key":"10.1016\/j.beha.2019.101133_bib55","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"10.1016\/j.beha.2019.101133_bib56","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","article-title":"Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm","volume":"32","author":"Fend","year":"2008","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.beha.2019.101133_bib57","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib58","first-page":"117","article-title":"Trisomy 14 in atypical chronic myeloid leukemia","volume":"4","author":"Mertens","year":"1990","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2019.101133_bib59","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2008.12.016","article-title":"t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia","volume":"277","author":"Micci","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.beha.2019.101133_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergen.2017.05.002","article-title":"Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq","volume":"216\u2013217","author":"Sheng","year":"2017","journal-title":"Cancer Genet"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12185-013-1381-1","article-title":"Atypical chronic myeloid leukemia harboring NUP98-HOXA9","volume":"98","author":"Murayama","year":"2013","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/fon-2017-0334","article-title":"Atypical chronic myeloid leukemia: a rare entity with management challenges","volume":"14","author":"Dhakal","year":"2018","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib64","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"11","key":"10.1016\/j.beha.2019.101133_bib65","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.101133_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique","volume":"78","author":"Martiat","year":"1991","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101133_bib67","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2019.101133_bib68","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.beha.2019.101133_bib69","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.101133_bib70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Cristobal","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.101133_bib71","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.beha.2019.101133_bib72","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2019.101133_bib73","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.beha.2019.101133_bib74","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","article-title":"Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia","volume":"120","author":"Lierman","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.101133_bib75","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Cristobal","year":"2011","journal-title":"Leukemia"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:40Z","timestamp":1761498400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619301276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692619301276"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.101133","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical CML- the role of morphology and precision genomics","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.101133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101133"}}